Great news! China's new coronavirus vaccine approved for listing: China Pharmaceutical Group China Bio-New Crown Inactivated Vaccine was approved conditional listing, free of charge to the whole people!

December 31, 2020 // -- The Joint Prevention and Control Mechanism of the State Council held a press conference today (December 31).
The Ministry of Science and Technology, the National Health And Safety Commission, the State Drug Administration, the Ministry of Foreign Affairs, the Ministry of Industry and Information Technology responsible for the vaccine research and development experts, the head of the National Pharmaceutical Group introduced the new coronavirus vaccine and answered questions.
(release video, see: the State Council joint prevention and control mechanism held a new coronavirus vaccine conditional listing and related work situation release) at the press conference, December 30, the National Pharmaceutical Group of China Bio-New Coronary Inactivated Vaccine was approved by the State Drug Administration conditional listing.
available data show that the protection rate is 79.34 percent, achieving the unity of safety, effectiveness, accessability and affordability, and meeting the relevant standards of the World Health Organization and the National Drug Administration.
, on December 9th and 13th, the United Arab Emirates and Bahrain, respectively, have approved the official registration of the Chinese bio-inactivated vaccine, a pharmaceutical group, in accordance with the relevant technical standards of the World Health Organization. Wu Yonglin, President of China Biotechnology Co., Ltd.,
National Pharmaceutical Group, said: China Bio-New Crown Vaccine has conducted large-scale Phase III.III clinical trials in several countries, including the United Arab Emirates and Bahrain, the number of inoculations has exceeded 60,000, the sample size of the vaccinated population covers 125 nationalities, completed the evaluation of phased protection rate data, the results are now better than the target of clinical research, safety and effectiveness indicators exceed the World Health Organization's listed standards, and our nationally approved conditional listing work program can be effectively protected.
vaccine safety: good safety has been proven! Zeng Yixin, deputy director of the National Health and Health Commission and head of the vaccine research and development team of the Joint Prevention and Control Mechanism of the State Council, said: In the process of vaccine research and development and production, we always put the safety and effectiveness of vaccines first.
In order to protect high-risk populations, in June this year, the principle of small-scale start-up, prudent, informed consent voluntary, under the premise of adequate adverse reaction monitoring and emergency preparedness, the high-risk population launched an emergency vaccination of the new crown vaccine.
to the end of November, more than 1.5 million doses had been given, of which about 60,000 had gone to work in high-risk areas abroad, no cases of serious infection had been reported, the safety of the vaccine had been fully demonstrated and its effectiveness had been verified.
On this basis, we all know that the winter and spring festival is the most common period of infectious disease outbreaks, in order to prevent the outbreak of the winter and spring festival, but also in order to effectively protect the relatively high risk of infection of the population, we officially launched on December 15 in China's key population vaccination work.
half a month, the country's key population has accumulated more than 3 million doses of vaccination.
In our vaccination work, we have established a series of systems, such as perfect vaccination point setting norms, strict training of inoculation personnel, screening of infected personnel, monitoring of adverse reactions, emergency treatment and expert consultation of severe adverse reactions, to ensure the safety and smoothness of vaccination work.
3 million this time, plus the previous 1.5 million, is a testament to the safety of our vaccine.
: orderly development, "should be connected" in the whole population to build an immune barrier! Zeng Yixin, deputy director of the National Health and Health Commission and head of the vaccine research and development team of the Joint Prevention and Control Mechanism of the State Council, said: The new crown pneumonia epidemic is a once-in-a-century infectious disease pandemic, and the global epidemic situation is still serious.
some of China's prevention and control has achieved strategic results, but the "foreign defense input, internal defense rebound" pressure is still very large.
With today's approval of conditional listing, especially with the gradual improvement of production and supply support capacity, we will comprehensively and orderly promote the elderly, high-risk groups with basic diseases vaccination, followed by other general population vaccination.
At present, China's expert advisory committee on immunization planning has developed a unified vaccination program, we will be in an orderly manner to carry out vaccination, eligible people are able to achieve "should be connected", and gradually build an immunization barrier in the whole population to block the spread of the new coronavirus, so that the new coronary pneumonia epidemic can be completely controlled.
vaccine price: fully free! Zheng Zhongwei, head of the vaccine research and development working group of the Joint Prevention and Control Mechanism of the State Council, said: With regard to the price of vaccines, we have always adhered to the main body of the enterprise when pricing.
but there are two principles that must be followed when it came to corporate pricing.
principle is the attribute of public goods, and the second principle, since it is public goods, can only be based on cost as a basis for pricing.
we all know that the cost of a product, its influence factors are also quite a lot, and its production scale, the scale of use is closely related.
think that with the approval of the vaccine conditional on the market, we are ready for large-scale production is about to start, and our immunization program is about to be pushed out.
as just introduced by Director Zeng, we will carry out the first step of high-risk groups, key groups, the second step of high-risk groups, the third step of the whole population vaccination.
costs will fall significantly as work is pushed away.
, we firmly believe that the price of the new coronavirus vaccine must be within the acceptable range of ordinary people.
Added: Just now Zhong Wei replied that the basic attributes of vaccines are still public goods, and prices may vary depending on the size of the use.
but the big premise is that it's certainly free for all, and that's a big premise.
() Origin: State Council Information Office